Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study in healthy volunteers will provide a basis for evaluation of TRL345 as a first in
human study, specifically, important safety, tolerability, and pharmacokinetic data, and
provide serum samples for ex vivo studies of concentration-dependent antiviral activity to
support the dose selection for as well as design and conduct of a clinical study in
transplant patients.
Phase:
Phase 1
Details
Lead Sponsor:
Trellis Bioscience LLC
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)